LY-320,135 is a drug used in scientific research which acts as a selective Antagonist (pharmacology), antagonist of the cannabinoid receptor cannabinoid receptor 1, CB₁. It was developed by Eli Lilly and Company in the 1990s. LY-320,135 displays fairly good selectivity, with a Dissociation constant, binding affinity for CB₁ around 70x stronger than for CB₂, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB₁ antagonists act as inverse agonists at higher doses.

References

Cannabinoids CB1 receptor antagonists Benzofuran ethers at the benzene ring Resorcinol ethers Aromatic ketones Benzonitriles Drugs developed by Eli Lilly and Company {{cannabinoid-stub